Sirisha L. Mushti

FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy

Dickran Kazandjian, Daniel L. Suzman, Gideon M. Blumenthal et al. · The Oncologist · 2016 · 473 citations · Full text

U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab

Maitreyee Hazarika, Meredith K. Chuk, Marc R. Theoret et al. · Clinical Cancer Research · 2017 · 181 citations

Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis

Julia A. Beaver, Maitreyee Hazarika, Flora Mulkey et al. · The Lancet Oncology · 2018 · 172 citations · Full text

Cancer Immunosurveillance, Medicine, Recist Progression +10

FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma

Sandra J. Casak, Leigh Marcus, Lola A. Fashoyin‐Aje et al. · Clinical Cancer Research · 2021 · 167 citations · Full text

FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with <i>RET</i> Gene Mutations or Fusions

Diana Bradford, Erin Larkins, Sirisha L. Mushti et al. · Clinical Cancer Research · 2020 · 161 citations